Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 6/20 | 0.56 |
| ▸ | MME | P08473 | 3/20 | 0.48 |
| ▸ | CASP1 | P29466 | 7/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | APEX1 | P27695 | 1/20 | 0.35 |
| ▸ | IL1B | P01584 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7088511 | 1.00 | ACE (0.56) | ACEMMECASP1CYP3A4TSHR | |
| SCHEMBL7088512 | 1.00 | ACE (0.56) | ACEMMECASP1CYP3A4TSHR | |
| SCHEMBL7339985 | 1.00 | ACE (0.56) | ACEMMECASP1CYP3A4TSHR | |
| Water SCHEMBL10565338 | 0.99 | ACE (0.54) | ACEMMECASP1CYP3A4TSHR | |
| SCHEMBL7348554 | 0.91 | ACE (0.46) | ACEMMECASP1CYP3A4TSHR | |
| SCHEMBL7348550 | 0.91 | ACE (0.46) | ACEMMECASP1CYP3A4TSHR | |
| SCHEMBL10567698 | 0.91 | ACE (0.46) | ACEMMECASP1CYP3A4TSHR | |
| SCHEMBL6627295 | 0.88 | ACE (0.43) | ACEMMECASP1CYP3A4TSHR | |
| SCHEMBL14078890 | 0.87 | ACE (0.42) | ACEMMECASP1CYP3A4TSHR | |
| SCHEMBL10567318 | 0.87 | ACE (0.64) | ACEMMECYP3A4TSHRTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11698375-B2 | Method for producing an examination reagent and kit for analysing a T-cell frequency | CONSTRUCTOR UNIVERSITY BREMEN GGMBH (DE) | 2023-07-11 | — | — | US | disclosed |
| US-20190331681-A1 | METHOD FOR PRODUCING AN EXAMINATION REAGENT AND KIT FOR ANALYSING A T-CELL FREQUENCY | JACOBS UNIVERSITY BREMEN GGMBH (DE) | 2019-10-31 | — | — | US | disclosed |
| US-10386367-B2 | Method for producing an examination reagent and kit for analysing a T-cell frequency | JACOBS UNIVERSITY BREMEN GGMBH (DE) | 2019-08-20 | — | — | US | disclosed |
| EP-2800974-B1 | METHOD FOR PRODUCING AN EXAMINATION REAGENT AND KIT FOR ANALYSING A T-CELL FREQUENCY | JACOBS UNIV BREMEN GMBH (DE) | 2016-12-14 | — | — | EP | disclosed |
| US-20140370524-A1 | METHOD FOR PRODUCING AN EXAMINATION REAGENT AND KIT FOR ANALYSING A T-CELL FREQUENCY | JACOBS UNIVERSITY BREMEN GGMBH (DE) | 2014-12-18 | — | — | US | disclosed |
| US-20120165319-A1 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-06-28 | — | — | US | disclosed |
| US-8119631-B2 | Inhibitors of interleukin-1β converting enzyme | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-02-21 | — | — | US | disclosed |
| US-7790713-B2 | Inhibitors of interleukin-1β converting enzyme | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-09-07 | — | — | US | disclosed |
| US-7772366-B2 | Inhibitors of interleukin-1β converting enzyme | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-08-10 | — | — | US | disclosed |
| US-20080070953-A1 | Inhibitors of interleukin-1 beta converting enzyme | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-03-20 | — | — | US | disclosed |
| US-20080039449-A1 | Inhibitors of interleukin-1beta converting enzyme | BATCHELOR MARK J | 2008-02-14 | — | — | US | disclosed |
| US-7288624-B2 | Inhibitors of interleukin-1β converting enzyme | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-10-30 | — | — | US | disclosed |
| US-20050143436-A1 | Inhibitors of interleukin-1beta converting enzyme | VERTEX PHARMACEUTICALS INCORPORATED | 2005-06-30 | — | — | US | disclosed |
| US-6548664-B1 | Alkylation, hydrogenation, cyclization, condensation, deracemization | AVENTIS PHARMA S.A. (FR) | 2003-04-15 | — | — | US | disclosed |
| US-20020099042-A1 | Inhibitors of interleukin-1 beta converting enzyme | VERTEX PHARMACEUTICALS INCORPORATED | 2002-07-25 | — | — | US | disclosed |
| US-6423840-B1 | FORMING N-ACYLAMINO COMPOUND | VERTEX PHARMACEUTICALS INCORPORATED | 2002-07-23 | — | — | US | disclosed |
| US-6008217-A | AN ENZYME INHIBITOR AGAINST INTERLEUKIN-1B, FOR TREATING APOPTOSIS-MEDIATED DISEASES, INCLUDING INFLAMMATORY DISEASES, AUTOIMMUNE DISEASES, PROLIFERATIVE DISORDERS, INFECTIOUS DISEASES, AND DEGENERATIVE DISEASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1999-12-28 | — | — | US | disclosed |
| EP-0869967-A2 | INHIBITORS OF INTERLEUKIN-1$g(b) CONVERTING ENZYME | Vertex Pharmaceuticals Incorporated (US) | 1998-10-14 | — | — | EP | disclosed |
| WO-1997022619-A2 | INHIBITORS OF INTERLEUKIN-1β CONVERTING ENZYME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1997-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070953-A1 | Inhibitors of interleukin-1 beta converting enzyme | IL1B, IL1A, IL1R1 | ACE 6/4885MME 97/4885CASP1 5/4885 |
| US-20020099042-A1 | Inhibitors of interleukin-1 beta converting enzyme | IL1B, IL1A, IL1RN | ACE 5/4885MME 90/4885CASP1 6/4885 |
| US-20120165319-A1 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME | IL1A, IFNAR1, IL1B | ACE 16/4885MME 279/4885CASP1 6/4885 |
| US-20080039449-A1 | Inhibitors of interleukin-1beta converting enzyme | IL1A, IL1B, IFNAR1 | ACE 19/4885MME 327/4885CASP1 5/4885 |
| US-20050143436-A1 | Inhibitors of interleukin-1beta converting enzyme | IL1A, IL1B, IFNAR1 | ACE 20/4885MME 314/4885CASP1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.